Company News

You are here:

Home
News

PharmaJet Announces Addition of Paul LaBarre as VP Global Business Development

GOLDEN, Colo. — June 15, 2021 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Paul LaBarre, has joined the leadership team as Vice President, Global Business Development. Mr. LaBarre is a global business executive with over 20 years of global health experience across the innovation value chain including strategy, research, product development, and strategic business development, most notably with UNICEF and PATH. In this role he will be leading business development and commercialization strategies for the PharmaJet organization replacing Melissa Malhame who transitioned to a strategic advisory role for the company. Details

The Lancet Publication Confirms Viability of Intradermal Polio Vaccination

GOLDEN, Colo. — June 3, 2021 - A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence from previous publications that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV). Previous studies have shown that two doses of intradermally-delivered IPV (60% less vaccine) were more immunogenic than one full dose delivered intramuscularly. Intradermal fractional dose delivery also lowers the total cost of vaccination substantially. Details

PharmaJet presents Needle-free delivery of Covid-19 DNA vaccine results at World Vaccine Congress

GOLDEN, Colo. — April 27, 2021 — PharmaJet^®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the World Vaccine Congress on May 6. The presentation, entitled Progress of COVID-19 Vaccines with Needle-Free Delivery, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc. Details

Global NGO expands use of PharmaJet for Polio Eradication Campaigns

GOLDEN, Colo. — March 9, 2021 — PharmaJet ^® , the maker of innovative, needle-free injection technology, today announced that a global NGO (Non-governmental organization) has expanded the use of its Tropis^® Needle-free Injection System in polio eradication campaigns. The latest country addition, Somalia, adds to the already successful vaccination programs in Pakistan, Cuba, The Gambia and others.

Details

PharmaJet Announces Appointment of Marian Wentworth to Board of Directors

GOLDEN, Colo. — February 9, 2021 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Marian Wentworth has been appointed to its Board of Directors. Ms. Wentworth, President and CEO of Management Sciences for Health, is an accomplished global health executive with extensive experience in global strategy, innovation, and development. Details

PharmaJet and Diomics partner on SARS-CoV-2 immune response monitoring

GOLDEN, Colo. — November 17, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Tropis^® Needle-free Injection System will be used by Diomics, a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department of Defense to accelerate testing of its Diocheck^™ system and is expected to begin human clinical trials in December 2020. Details

University of Cambridge receives Multi-million Dollar Funding for Clinical Trial using PharmaJet’s Needle-free System to Deliver Vaccine to Prevent COVID-19

GOLDEN, Colo. — October 27, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial. The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently received multi-million dollar funding from the UK government to move forward with a clinical trial. Preparations for the clinical trial are well underway and the trial will begin as soon as possible. Details

PharmaJet’s Needle-free System to be used in Australian Clinical COVID-19 Trial

GOLDEN, Colo. — October 6, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Stratis^® Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial in Australia. The DNA-based vaccine COVIGEN was developed by French-Thai pharmaceutical company BioNet and Melbourne-based biotech Technovalia. The Phase 1 trial is a joint collaboration between Australia’s most experienced vaccine trial sites including the University of Sydney, the Telethon Kids Institute in Perth, the University of Adelaide, the Vax4COVID alliance, and with multi-million dollars financial support of Australia’s Medical Research Future Fund. Details

PharmaJet Announces Addition of Melissa Malhame as VP Business Development

GOLDEN, Colo. — September 29, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Melissa Malhame, has joined the leadership team as Vice President, Business Development. Ms. Malhame is a global business executive with over 25 years of experience in business development, strategic sales, and marketing for major vaccine providers such as Gavi, Dynavax and Merck, as well as supporting global health investments in new vaccine candidates and expanding access to existing vaccines. In this role she will be leading business development, sales, and marketing for the Pharmajet organization. Details

International Pharmaceutical Development Consortium to partner with PharmaJet for delivery of COVID-19 DNA Vaccine, GX-19

GOLDEN, Colo. — September 15, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Stratis® Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19 (GX-19) which is being developed by an international consortium led by Genexine, a leading biotherapeutics company headquartered in South Korea. The consortium also includes the International Vaccine Institute (IVI), Binex, GenNBio, Korea Advanced Institute for Science and Technology, and Pohang University of Science and Technology. Details